mHTT Phase-Separated Condensates Sequester Transcription Factors in Huntington's Disease: A Flory-Huggins Computational Framework for Condensate-Disrupting Therapy
Abstract
Mutant Huntingtin (mHTT) exon 1 undergoes polyQ-length-dependent liquid-liquid phase separation (LLPS) into gel-like condensates. We apply a Flory-Huggins polymer mixing framework as a two-point calibration of the published experimental phase boundary (Peskett et al. 2018), re-expressing those data in polymer-thermodynamic terms; the resulting polyQ-length-dependent phase diagram is illustrative rather than independently predictive. In this calibration, Q46-length protein crosses the phase boundary at a critical concentration of approximately 3.5 µM — physiologically accessible in HD striatal neurons. We propose transcription factor (TF) sequestration by condensate co-partitioning as a candidate downstream mechanism of mHTT toxicity. A sensitivity analysis shows the predicted magnitude is governed by the nuclear volume fraction of the mHTT phase, which current data do not constrain, rather than by the partition coefficients; at plausible volume fractions it falls one to two orders of magnitude below the mean −44.7% reduction in SP1/CBP/TFIID target gene expression reported in HD striatum. We hypothesize that BET bromodomain inhibitors (JQ1, OTX015) and mitoxantrone analogues can restore TF availability by disrupting mHTT condensates. Patent AU2026905785.
0/2 confirmed · 1 withdrawn
mHTT exon 1 at HD-length polyQ (≥Q40) undergoes LLPS at physiologically relevant concentrations (C* ≤ 5 µM in HD striatal neurons) and the resulting condensate phase sequesters transcription factors SP1, CBP/p300, and TFIID/TAF4 by thermodynamic co-partitioning, quantitatively contributing to the observed gene expression deficits in HD striatum.
Compounds with published condensate-disrupting activity in BRD4-containing super-enhancer condensates — specifically BET bromodomain inhibitors (JQ1, OTX015) and mitoxantrone analogues — will reduce the FRAP half-life of mHTT exon 1 Q46 condensates by ≥30% at concentrations ≤10 µM in a validated in vitro assay, and restore SP1/CBP/p300 nuclear availability in HD neuronal models.
Key Findings
- 1H₁ (illustrative calibration): Flory-Huggins two-point calibration anchored to Peskett et al. 2018 gives C* ≈ 3.5 µM for Q46; wildtype Q23 never phase-separates — a re-expression of the published boundary, not an independent prediction
- 2TF partition coefficients predict depletion, but a parameter sweep shows the magnitude is set by the unconstrained mHTT nuclear volume fraction — the −44.7% striatal deficit is not accounted for at plausible values
- 3H₂ withdrawn, not tested: the BET-inhibitor rescue was a rescue of H₁'s mechanism, and its Phase 3 readout (BDNF, PGC-1α) is flat in HD caudate at every Vonsattel grade including grade 0 — there is no downstream signature for the experiment to restore
Source Discoveries
Hypotheses in this paper were sourced from the following AegisMind discoveries on solver.press.
196 days
Timeline
80
CPU hours
16 GB
Memory
$95k
Budget (min)
$280k
Budget (full)
Required Datasets
Phase 1: Recombinant mHTT exon 1 (Q23, Q46, Q72); JQ1 (Cayman 11187), OTX015 (Selleckchem S7360), mitoxantrone (Sigma M6545); confocal microscope with FRAP module. Phase 2: HEK293 cells; mHTT exon 1 Q46-EGFP and Q23-EGFP constructs; anti-SP1, anti-CBP/p300 antibodies for co-IP and immunofluorescence. Phase 3: Q175 knock-in mouse primary striatal neurons or HD iPSC-derived neurons (Coriell GM04281); the active condensate-dissolving compound from Phase 1; RT-qPCR for BDNF and PGC-1α.
Experimental Protocol
Phase 1 (4 weeks): Recombinant Q23/Q46/Q72 mHTT exon 1 purified; condensates formed at 5 µM. Test JQ1, OTX015, mitoxantrone at 0.1, 1, 10, 100 µM. FRAP half-life at 488 nm. Success: ≥1 compound achieves ≥30% FRAP reduction in Q46 at ≤10 µM, no effect on Q23.
Phase 2 (8 weeks): HEK293 cells transfected with Q46-EGFP and Q23-EGFP. Co-IP of SP1 and CBP/p300 with mHTT under compound treatment (active compounds from Phase 1). Success: ≥50% reduction in co-IP, ≥1.5-fold nuclear:cytoplasmic ratio increase by immunofluorescence.
Phase 3 (16 weeks): the active condensate-dissolving compound from Phase 1 applied to Q175 KI mouse striatal neurons or HD iPSC neurons. Endpoints: BDNF and PGC-1α mRNA (RT-qPCR), cell viability (MTT) at 28 days.
Success Criteria
Phase 1: ≥1 compound achieves FRAP half-life reduction ≥30% in Q46 condensates at ≤10 µM; no effect on Q23 (polyQ-specificity). Phase 2: ≥50% reduction in SP1/CBP/p300 co-IP with mHTT Q46 under active compound vs. vehicle; nuclear:cytoplasmic ratio ≥1.5-fold increase. Phase 3: BDNF mRNA rescue ≥20% in the condensate-dissolving arm.
Failure Criteria
Phase 1: No compound achieves ≥30% FRAP reduction at ≤10 µM — H₂ falsified for this compound class. Phase 2: Co-IP unchanged, nuclear localisation unchanged — condensate dissolution does not restore TF availability. Phase 3: No rescue in either monotherapy arm — one or both upstream mechanisms not operating in neuronal model.
Abort Checkpoints
Phase 1, Week 2: Abort if no compound achieves ≥10% FRAP reduction at 100 µM. Phase 2, Week 4: Abort if recombinant condensates do not form at 5 µM Q46. Phase 3, Week 8: Abort if primary neurons show <10% viability under the condensate-dissolving compound at target dose.
Commercial ROI
OTX015/birabresib is CNS-penetrant with completed Phase I/II oncology trials (NCT01713582) — if H₂ is confirmed, an HD repositioning IND can leverage the existing safety dossier. Combined BD value: 30,000 HD patients in the US (no approved DMT); comparable neurodegeneration asset deals ~$1B+.
Research ROI
First direct experimental test of condensate co-partitioning as a mechanism for mHTT toxicity (vs. stoichiometric binding). Confirmation of H₂ would establish a new therapeutic modality (condensate dissolution) for HD and potentially other polyQ diseases (SCA, SBMA).
Aggregated EVP Package
This paper is part of the Quantum-ML Convergence EVP cluster. The aggregated EVP combines evidence from multiple papers targeting related mechanisms, enabling shared experimental infrastructure and compounded validation.
View aggregated EVP →